Insilico Medicine (03696.HK) Surges Over 12% After Announcing Expanded AI-Driven CNS Collaboration with Tenacia Biotechnology

According to the Zhitong Finance APP, Insilico Medicine (03696) surged over 12% in the afternoon session, and as of press time, it was up 11.93%, trading at HK$56.3, with a turnover of HK$136 million.

On the news front, Insilico Medicine announced that the company has reached an expanded AI-driven R&D collaboration with Yuanyi Biotechnology (Shanghai) Co., Ltd. The collaboration will utilize generative AI to target challenging neurological diseases, jointly developing an innovative candidate molecule with specific attributes and advancing it to the preclinical candidate (PCC) stage. Reportedly, the total value of this expanded collaboration could reach up to $94.75 million.

Notably, this is the fourth collaboration with Chinese pharmaceutical companies announced by Insilico Medicine since its listing on the Hong Kong Stock Exchange on December 30, 2025. Previously, the company's collaboration with Yuanyi Biotechnology (Shanghai) Co., Ltd. focused on the treatment of central nervous system diseases; its partnership with Qilu Pharmaceutical Co., Ltd. concentrated on cardiovascular and metabolic diseases; and it reached a series of AI-powered innovative drug R&D collaborations with CMS (CHINA MEDICAL SYSTEM HOLDINGS LIMITED) on multiple projects in the fields of central nervous system and autoimmune diseases.